Related Experiment Video

Updated: Jul 12, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Risk factors for the development of bronchiectasis in HIV-infected children

David M Berman1, Damaris Mafut, Boris Djokic

  • 1Division of Pediatric Infectious Disease and Special Immunology, University of Miami School of Medicine, Jackson Memorial Medical Center, Miami, Florida 33701, USA. bermand@allkids.org

Pediatric Pulmonology
|August 28, 2007
PubMed

Insights

Recurrent pneumonia, severe immunosuppression (CDC category 3), and lymphoid interstitial pneumonitis (LIP) increase the risk of bronchiectasis in children with HIV-1. Early identification of these factors is crucial for prevention.

Area of Science:

  • Pediatric Infectious Diseases
  • Pulmonology
  • Immunology

Background:

  • Bronchiectasis is a serious complication in children with Human Immunodeficiency Virus type 1 (HIV-1) infection.
  • Identifying risk factors is essential for timely intervention and improved patient outcomes.

Purpose of the Study:

  • To determine the risk factors associated with the development of bronchiectasis in pediatric HIV-1 patients.
  • To analyze the relationship between pneumonia history, immunosuppression levels, and specific lung conditions with bronchiectasis.

Main Methods:

  • A retrospective, case-controlled study was conducted reviewing medical records of HIV-1 infected children.
  • Cases with bronchiectasis were matched with controls without bronchiectasis based on birth dates.
  • Variables analyzed included pneumonia episodes (Pneumocystis jiroveci pneumonitis [PCP], lymphoid interstitial pneumonitis [LIP]), and CDC immunosuppression categories.

Main Results:

  • Children who developed bronchiectasis had significantly higher rates of recurrent pneumonia (89.5% vs. 8.8%) and a greater mean number of pneumonia episodes (8.2 vs. 1.45).
  • Cases were more likely to have progressed to CDC immunological category 3 (100% vs. 56%).
  • Lymphoid interstitial pneumonitis (LIP) was more frequent in cases (73.6%) compared to controls (33.3%).

Conclusions:

  • Recurrent pneumonia, profound immunosuppression (CDC category 3), and LIP are significant risk factors for bronchiectasis in HIV-1 infected children.
  • These findings highlight the importance of monitoring respiratory health and immune status in this population.

More Related Videos

Murine Intrapulmonary Tracheal Transplantation: A Model for Investigating Obliterative Airway Disease After Lung Transplantation06:15

Murine Intrapulmonary Tracheal Transplantation: A Model for Investigating Obliterative Airway Disease After Lung Transplantation

Published on: November 10, 2023

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...